Deel, the Leading Platform for Global Hiring and Payments, Acquires Zeitgold to Strengthen Payroll & AI Offerings
4.8.2021 10:06:00 EEST | Business Wire | Press release
Deel, the market leader in the global payroll and compliance space, announced today that it had joined forces with Zeitgold to fuel international growth and enhance the depth and breadth of its product offerings. This acquisition marks a significant milestone for Deel as the company continues to scale, adding thousands of customers as working and hiring practices continue to transform rapidly. Deel is adding a full line of products through this acquisition to improve their customer experience further and provide them with the right solutions to scale internationally.
Deel enables businesses to hire anyone, anywhere, in a compliant manner. With Deel, hiring and onboarding international employees or contractors takes under 5 minutes, with no local entity required. Businesses can also pay their teams in 120+ currencies with just a click. In April 2021, Deel raised $156 million in Series C funding at a $1.25 billion valuation. With their new funding, Deel announced plans to continue international expansion, grow its team through mergers & acquisitions, hire exceptional talent globally, all while improving, building, and expanding its product offerings. The purchase of Zeitgold marks the first step in the company’s extensive M&A plans and reinforces its global payroll offering.
Zeitgold was founded in 2015 by Jan Deepen and Stefan Jeschonnek, co-founders of SumUp, the European fintech unicorn, and Kobi Eldar, a former senior intelligence officer of the prestigious 8200 Israeli unit. Zeitgold has raised over $60M from leading venture capital firms such as Battery Ventures, Vintage Investment Partners, HV Holtzbrinck Ventures, as well as insurance company AXA and Deutsche Bank. All existing Zeitgold investors will now be joining Deel as shareholders.
Zeitgold offers AI-powered payroll and automated bookkeeping software for businesses and contractors. The contractor product assists thousands of independent contractors with their setup, bookkeeping, and tax filing. Zeitgold’s highly skilled team and impressive track record have made it a gem of the German technology industry. With this purchase, Deel is adding senior leadership to its ranks and gains the expertise of Zeitgold’s team in global payroll, automation, and AI. The deal also provides valuable IP in global payroll processing based on a powerful workflow engine and document understanding AI stack, which Deel will leverage to scale up and serve hundreds of thousands of clients.
"With the addition of Zeitgold, we'll accelerate even faster and reinforce our European leadership," said Deel CEO Alex Bouaziz. "We're taking Zeitgold's best-in-class engine and plugging it into the core of our platform to help Deel supercharge its product offerings."
"By joining forces with Deel, we can leverage our core technology and products at a global scale," said Zeitgold CEO Jan Deepen. "The new capabilities we're bringing to Deel will allow contractors and employees all over the world to stay compliant and take care of their payroll with confidence, all while continuing to help reduce hiring barriers worldwide."
Deel was co-founded in 2018 by MIT alumni Bouaziz and Wang. The founders set out to solve a problem that most businesses worldwide found daunting—the ability to hire people from anywhere easily. In the past 12 months, the company grew by more than 1000% in revenue to support over 3,000 businesses worldwide. It has plans to set up 100 new Deel-owned entities across the world by the end of 2021. With the acquisition of Zeitgold, Deel plans to deploy this offering into every country where it operates, shattering hiring barriers worldwide.
About Deel
Deel is a global compliance and payroll solution that helps businesses hire anyone, anywhere. Using a tech-enabled self-serve process, companies can now hire independent contractors and full-time employees in over 150 countries, compliantly and in minutes. Deel enables any business to compliantly create, sign, and send localized contracts from a library of templates. Deel automates the process of collecting country-specific documents like tax documents from contractors and employees to ensure they get set up to work correctly. The platform also allows companies to pay international contractors and employees in more than 120 currencies with just a few clicks. Learn more about Deel here.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210804005322/en/
Contact information
Lisa Tarter
lisa@tidalwavepr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
